ArticlePloS one2025
Motivations, perceived risk, and tampering of XTAMPZA ER and abuse-deterrent opioid drugs.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Behavioral and social pathways of adolescent drug use in Indonesia: implications for community-based prevention.BMC public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abuse deterrent formulation (ADF) products are designed to prevent people from tampering with medication, especially with the intention to misuse or abuse the product. While clinical results support the efficacy of ADF products in controlled settings, little is known about how people use and abuse them in the real world. The objective of this research was to describe tampering behavior and perceived risk among U.S. adults who report non-medical use (NMU) of XTAMPZA® ER, a novel ADF extended-release opioid, and comparable products. A cross-sectional survey was conducted in 2021 and 2022 among adults who reported NMU of oxycodone or hydrocodone products in the past year. To compare use patterns and tampering behavior to XTAMPZA® ER, three similar opioid products were also assessed. Participants who reported NMU of an eligible drug were asked why they used it, how they tempered with it, and what other drug-related behaviors they engaged in. A total of 628 participants were recruited. A total of 56 (8.92%) reported NMU of XTAMPZA® ER in the past year, 256 (40.8%) reported NMU of other ADF ER oxycodone/hydrocodone, 459 (73.1%) reported NMU of non-ADF ER oxycodone/hydrocodone, and 225 (35.8%) reported NMU of IR oxycodone. Non-ADF ER oxycodone/hydrocodone was the most used. Those who reported NMU of XTAMPZA® ER had more severe drug use profiles, including higher scores on the 10-item Drug Abuse Screening Test (DAST-10) and higher prevalence of concomitant and illicit drug use. Overall, 3.7% tampered with XTAMPZA® ER, 12.9% tampered with other ADF ER oxycodone/hydrocodone, 16.0% tampered with non-ADF ER oxycodone/hydrocodone, and 10.7% tampered with IR oxycodone. U.S. adults who reported tampering with XTAMPZA® ER or a comparable product frequently did so for therapeutic reasons, most commonly "to swallow the pill more easily" and "to improve the pain relief from the pill." They also viewed tampering with products they used as less risky than tampering with products they did not use. Tampering with XTAMPZA® ER was uncommon compared to other drugs but more common as a proportion among those who used XTAMPZA® ER. This is, potentially because those using XTAMPZA® ER had other markers of severe, problematic drug use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.